MRKR MRKR

Marker Therapeutics Stock Price

FREE MRKR REPORT

3.13
2.78 (787.19%)
Upgrade to Real-Time
Afterhours (Closed)
3.13
Volume 157,986
Bid Price 3.01
Ask Price 3.13
News -
Day High 3.49

Low
2.20

52 Week Range

High
6.70

Day Low 2.86
Company Name Stock Ticker Symbol Market Type
Marker Therapeutics Inc MRKR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
2.78 787.19% 3.13 19:39:09
Open Price Low Price High Price Close Price Prev Close
3.46 2.86 3.49 3.117 0.3528
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,008 157,986 $ 3.09 $ 488,817 - 2.20 - 6.70
Last Trade Time Type Quantity Stock Price Currency
19:55:16 75 $ 3.03 USD

Period:

Draw Mode:

Marker Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 261.67M 83.60M 58.84M $ 1.24M $ - -0.56 -0.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 21.30%

more financials information »

Marker Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MRKR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.0124.36452.863.80531,2690.1183.92%
1 Month2.404.36452.3113.45364,9000.7330.42%
3 Months4.2354.472.203.21311,873-1.11-26.09%
6 Months3.2216.602.204.711,123,860-0.091-2.83%
1 Year6.106.702.204.57758,248-2.97-48.69%
3 Years29.6037.702.2017.18872,734-26.47-89.43%
5 Years100.10102.502.2023.01723,806-96.97-96.87%

Marker Therapeutics Description

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.